The present disclosure relates to the treatment of lung, liver, and/or kidney injury, by administering to a subject in need thereof a therapeutically effective amount of a (very) long acting C-type natriuretic peptide (CNP), CNP derivative, (very) long acting CNP derivative, or (very) long acting CNP receptor (NPRB) agonist. The disclosure also relates to the treatment of non-cardiovascular causes of low blood oxygenation, elevated levels of inflammatory cells in the lung, pulmonary edema, sepsis, bacteremia, fibrosis in general, and/or interstitial lung disease using the same.

The present disclosure relates to the treatment of lung, liver, and/or kidney injury, by administering to a subject in need thereof a therapeutically effective amount of a (very) long acting C-type natriuretic peptide (CNP), CNP derivative, (very) long acting CNP derivative, or (very) long acting CNP receptor (NPRB) agonist. The disclosure also relates to the treatment of non-cardiovascular causes of low blood oxygenation, elevated levels of inflammatory cells in the lung, pulmonary edema, sepsis, bacteremia, fibrosis in general, and/or interstitial lung disease using the same.

This disclosure relates to anti-Natriuretic Peptide Receptor 1 (NPR1) antibodies including agonist antibodies which are able to activate the NPR1 receptor, pharmaceutical compositions comprising the same, and methods of treatment comprising the same.

Disclosed are a novel N-terminal fusion partner, a fusion polypeptide including the fusion partner and a target polypeptide, and a method for producing a target polypeptide using the same. The novel fusion partner can enhance the yield of a target polypeptide (recombinant polypeptide) compared to the conventional fusion partners. Using the novel fusion partner is particularly beneficial in producing a target polypeptide having a relatively low molecular weight and an easily degradable amino terminus based on genetic recombination technologies. Further, the novel fusion polypeptide including the fusion partner can be expressed as inclusion bodies in a host cell and protected against proteases or the like in a host cell, which makes the target polypeptide produced stably. Therefore, in comparison to the conventional fusion partners, the novel fusion partner can be used to provide a method for producing a recombinant peptide with improved stability and yield.

Disclosed are a novel N-terminal fusion partner, a fusion polypeptide including the fusion partner and a target polypeptide, and a method for producing a target polypeptide using the same. The novel fusion partner can enhance the yield of a target polypeptide (recombinant polypeptide) compared to the conventional fusion partners. Using the novel fusion partner is particularly beneficial in producing a target polypeptide having a relatively low molecular weight and an easily degradable amino terminus based on genetic recombination technologies. Further, the novel fusion polypeptide including the fusion partner can be expressed as inclusion bodies in a host cell and protected against proteases or the like in a host cell, which makes the target polypeptide produced stably. Therefore, in comparison to the conventional fusion partners, the novel fusion partner can be used to provide a method for producing a recombinant peptide with improved stability and yield.

The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).

The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).

The present invention relates to a polypeptide carrying a human BNP(1-32) epitope according to Formula (I): a.sub.1-R.sub.1-X.sub.1-FGRKMDR-X.sub.2-R.sub.2-a.sub.2 as well as ligands specific of the FGRKMDR epitope.

The present invention relates to a polypeptide carrying a human BNP(1-32) epitope according to Formula (I): a.sub.1-R.sub.1-X.sub.1-FGRKMDR-X.sub.2-R.sub.2-a.sub.2 as well as ligands specific of the FGRKMDR epitope.

This disclosure provides a natriuretic peptide derivative of Formula (I), and to compositions including a natriuretic peptide derivative of Formula (I),

(fatty acyl).sub.z-(B).sub.x-(G).sub.y-NP (I),

wherein: z is 1, x is an integer from 2 to 4 and y is 3; or z is 0, x is an integer from 0 to 4 and y is an integer from 1 to 3; fatty acyl comprises from 12 to 24 (e.g., 12 to 18) carbons atoms; B is lysine or arginine; G is glycine; NP is a natriuretic peptide; if present, (fatty acyl).sub.z- is covalently linked to the N-terminus of (B).sub.x; (fatty acyl).sub.z-(B).sub.x- is covalently linked to the N-terminus of (G).sub.y; and (fatty acyl).sub.z-(B).sub.x-(G).sub.y- is covalently linked to the N-terminus of NP. The natriuretic peptide derivative according to the disclosure, and compositions thereof, are useful in the treatment of diseases such as hypertension, vascular congestion, and heart disease.